The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Open accessAbstract
Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5 . Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need 6,7 . Here we report the progressive accumulation of exhausted, unconventionally activated CD8 + PD1 + T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8 + PD1 + T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH–HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8 + PD1 + CXCR6 + , TOX + , and TNF + T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8 + T cells or TNF neutralization, suggesting that CD8 + T cells help to induce NASH–HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8 + PD1 + T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH–HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Focusing our analysis on the CD4+ T cell compartment, we identified FOXP3+ cells expressing canonical Treg cell transcripts, including IL2RA, CTLA4 and TNFRSF18 (Fig. 1D, right panel).”
From Regulatory T cells safeguard liver health during metabolic-associated steatohepatitis (2026) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, CXCR6+PD-1+CD8+ T cells also accumulate in tumors that are unresponsive to anti–PD-1 therapy [17]”
From Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We delineated a fibrosis-related enrichment of CD8+ TEM cells harboring a previously reported exhausted signature31,34,35 in the liver, whereas the frequency of CD8+ TEMRA cells increased in the peripheral blood with liver steatosis as assessed by CAP”
The cited source says what the claim attributes to it.
In the citing paper
“Results from other studies suggest that a metabolic-related fatty liver disease-related aetiology might be related to a decreased response owing to unique immunological traits hampering antitumoural surveillance11,101.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“preclinical evidence suggests that mice with pure metabolic dysfunction-associated steatohepatitis (MASH)-related HCCs may not benefit from ICIs.”
From Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis (2025) · cites this paper as [22]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citation
Cited by
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Self-citationMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Self-citationGinès, P., Krag, A., Abraldes, J. G., Solà, E., Fabrellas, N., & Kamath, P. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01374-x · Cited by 1,663
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Metadata
- Authors
- Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., Müller, F., Sinha, A., Friebel, E., Engleitner, T., Lenggenhager, D., Moncsek, A., Heide, D., Stirm, K., Kosla, J., Kotsiliti, E., Leone, V., Dudek, M., Yousuf, S., Inverso, D., Singh, I., Teijeiro, A., Castet, F., Montironi, C., Haber, P. K., Tiniakos, D., Bedossa, P., Cockell, S., Younes, R., Vacca, M., Marra, F., Schattenberg, J. M., Allison, M., Bugianesi, E., Ratziu, V., Pressiani, T., D’Alessio, A., Personeni, N., Rimassa, L., Daly, A. K., Scheiner, B., Pomej, K., Kirstein, M. M., Vogel, A., Peck-Radosavljevic, M., Hucke, F., Finkelmeier, F., Waidmann, O., Trojan, J., Schulze, K., Wege, H., Koch, S., Weinmann, A., Bueter, M., Rössler, F., Siebenhüner, A., De Dosso, S., Mallm, J.-P., Umansky, V., Jugold, M., Luedde, T., Schietinger, A., Schirmacher, P., Emu, B., Augustin, H. G., Billeter, A., Müller-Stich, B., Kikuchi, H., Duda, D. G., Kütting, F., Waldschmidt, D.-T., Ebert, M. P., Rahbari, N., Mei, H. E., Schulz, A. R., Ringelhan, M., Malek, N., Spahn, S., Bitzer, M., Ruiz de Galarreta, M., Lujambio, A., Dufour, J.-F., Marron, T. U., Kaseb, A., Kudo, M., Huang, Y.-H., Djouder, N., Wolter, K., Zender, L., Marche, P. N., Decaens, T., Pinato, D. J., Rad, R., Mertens, J. C., Weber, A., Unger, K., Meissner, F., Roth, S., Jilkova, Z. M., Claassen, M., Anstee, Q. M., Amit, I., Knolle, P., Becher, B., Llovet, J. M., & Heikenwalder, M.
- Affiliations
- German Cancer Research Center (DE)
- University of Zurich (CH)
- Hospital Clínic de Barcelona (ES)
- Newcastle University (GB)
- Medical University of Vienna (AT)
- Universitätsklinikum Tübingen (DE)
- University Hospital Heidelberg (DE)
- Weizmann Institute of Science (IL)
- TUM Klinikum (DE)
- University Hospital Zurich (CH)
- Technical University of Munich (DE)
- Spanish National Cancer Research Centre (ES)
- Icahn School of Medicine at Mount Sinai (US)
- National and Kapodistrian University of Athens (GR)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- University of Florence (IT)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University of Cambridge (GB)
- Hôpital Beaujon (FR)
- Humanitas University (IT)
- Medizinische Hochschule Hannover (DE)
- Klinikum Klagenfurt (AT)
- University Hospital Frankfurt (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Heinrich Heine University Düsseldorf (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Massachusetts General Hospital (US)
- University of Cologne (DE)
- Heidelberg University (DE)
- German Rheumatism Research Centre (DE)
- University of Tübingen (DE)
- Mount Sinai Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- Kindai University (JP)
- Taipei Veterans General Hospital (TW)
- Centre National de la Recherche Scientifique (FR)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Helmholtz Munich (DE)
- Max Planck Institute of Biochemistry (DE)
- NIHR Newcastle Biomedical Research Centre (GB)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Llovet, Josep M.
- ORCID
- Pfister, Dominik
- Núñez, Nicolás Gonzalo
- Pinyol, Roser
- Govaere, Olivier
- Pinter, Matthias
- Szydlowska, Marta
- Gupta, Revant
- Deczkowska, Aleksandra
- Weiner, Assaf
- Sinha, Ankit
- Friebel, Ekaterina
- Engleitner, Thomas
- Lenggenhager, Daniela
- Moncsek, Anja
- Heide, Danijela
- Stirm, Kristin
- Kosla, Jan
- Dudek, Michael
- Inverso, Donato
- Singh, Indrabahadur
- Teijeiro, Ana
- Castet, Florian
- Montironi, Carla
- Haber, Philipp K.
- Tiniakos, Dina
- Cockell, Simon
- Younes, Ramy
- Vacca, Michele
- Marra, Fabio
- Schattenberg, Jörn M.
- Allison, Michael
- Bugianesi, Elisabetta
- Ratziu, Vlad
- Pressiani, Tiziana
- D’Alessio, Antonio
- Personeni, Nicola
- Rimassa, Lorenza
- Daly, Ann K.
- Scheiner, Bernhard
- Pomej, Katharina
- Kirstein, Martha M.
- Vogel, Arndt
- Peck-Radosavljevic, Markus
- Hucke, Florian
- Finkelmeier, Fabian
- Waidmann, Oliver
- Trojan, Jörg
- Schulze, Kornelius
- Wege, Henning
- Koch, Sandra
- Weinmann, Arndt
- Bueter, Marco
- Rössler, Fabian
- Siebenhüner, Alexander
- Mallm, Jan-Philipp
- Umansky, Viktor
- Luedde, Tom
- Schietinger, Andrea
- Schirmacher, Peter
- Emu, Brinda
- Augustin, Hellmut G.
- Billeter, Adrian
- Müller-Stich, Beat
- Kikuchi, Hiroto
- Duda, Dan G.
- Ebert, Matthias Philip
- Rahbari, Nuh
- Mei, Henrik E.
- Schulz, Axel Ronald
- Ringelhan, Marc
- Malek, Nisar
- Spahn, Stephan
- Bitzer, Michael
- Lujambio, Amaia
- Dufour, Jean-Francois
- Marron, Thomas U.
- Kaseb, Ahmed
- Kudo, Masatoshi
- Huang, Yi-Hsiang
- Djouder, Nabil
- Wolter, Katharina
- Zender, Lars
- Decaens, Thomas
- Pinato, David J.
- Rad, Roland
- Mertens, Joachim C.
- Weber, Achim
- Unger, Kristian
- Meissner, Felix
- Roth, Susanne
- Claassen, Manfred
- Anstee, Quentin M.
- Amit, Ido
- Knolle, Percy
- Becher, Burkhard
- Llovet, Josep M.
- Heikenwalder, Mathias
- Venue
- Nature
- Published
- 2021-03-24
- Volume
- 592
- Issue
- 7854
- Pages
- 450-456
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8046670
- OpenAlex
- W3138484572
- Cited by
- 1,294
- References
- 70
- Citations by year
- 2026: 206 · 2025: 195 · 2024: 250 · 2023: 272 · 2022: 249 · 2021: 114
- FWCI
- 81.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
- Lirias (acceptedVersion, cc-by)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- HAL (submittedVersion)
- HAL (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- BORIS (University Library Bern) (submittedVersion, cc-by)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, cc-by)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
- mediaTUM (Technical University of Munich) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- Apollo
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Science Foundation (310030)
- U.S. Department of Defense (CA150272P3)
- Howard Hughes Medical Institute (724471-HemTree2.0, 509044)
- National Multiple Sclerosis Society (PA-1604-08459)
- Conquer Cancer Foundation (14704)
- Gilead Sciences (272983813)
- American Society of Clinical Oncology (14704)
- Memorial Sloan-Kettering Cancer Center
- Deutsches Krebsforschungszentrum (272983813, 70113167, CA181, 70112720)
- Wilhelm Sander-Stiftung
- Wellcome Trust (PS3416, 310030, 667273)
- Westminster Medical School Research Trust
- Chan Zuckerberg Initiative
- Thompson Family Foundation
- International Progressive MS Alliance (PA-1604-08459)
- Cancer Research UK (C9380/A268-13, A26137, A26813, 26813, C9380, C57701/A26137, C57701)
- National Institute for Health and Care Research (777377)
- University of Cambridge
- Imperial College London
- Imperial College Healthcare NHS Trust
- Newcastle University
- European Commission (777377, 634413, HORIZON2020, 667273)
- Wolfson Foundation
- Deutsche Forschungsgemeinschaft (SFB1335, 634413, EXC2180, EXC 2180—390 900 677, RTG2099, Me‐3644/5‐1, SFB TR 179, 360372040, SFB/TR-209, 314905040, HA 8754/1-1, 272983813, FOR-2314, 777377, 259332240, 390900677)
- Universität Heidelberg
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (150768, 170320, 183478, 182679, 310030)
- Weizmann Institute of Science
- Ministry of Science, Technology and Space
- Eberhard Karls Universität Tübingen (390900677, EXC 2180)
- Bundesministerium für Bildung und Forschung (031B0686B)
- Fundación Científica Asociación Española Contra el Cáncer (C9380/A26813)
- Generalitat de Catalunya (SGR‐1358, PID2019)
- Universität Wien
- Fonds Wetenschappelijk Onderzoek (30826052)
- Israel Science Foundation (703/15)
- Johannes Gutenberg-Universität Mainz
- Gottfried Wilhelm Leibniz Universität Hannover
- Università degli Studi di Firenze
- Associazione Italiana per la Ricerca sul Cancro (A26813, P30-CA196521, C9380/A26813)
- National and Kapodistrian University of Athens
- Medizinischen Hochschule Hannover
- Universitat de Barcelona
- Medizinische Universität Wien
- Deutsche Krebshilfe (70113167, SFB/TR 209, 70113166, 70112720)
- Universität Zürich
- Università degli Studi di Torino
- Universitätsspital Zürich
- Humanitas University
- Assistance publique-Hôpitaux de Paris
- Fakultet Medicinskih Nauka, Univerziteta U Kragujevcu
- Innovative Medicines Initiative (777377)
- Vlaamse regering
- Deutschen Konsortium für Translationale Krebsforschung
- Universitätsklinikum Heidelberg
- National Institutes of Health (UL1TR001863)
- Weill Cornell Graduate School of Medical Sciences
- Imperial Experimental Cancer Medicine Centre
- Medical Research Council
- Leibniz-Gemeinschaft
- Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR-1358)
- Instituto de Salud Carlos III (CM19/00039)
- Faculty of Medical Sciences, Newcastle University
- Medizinischen Fakultät, Eberhard Karls Universität Tübingen
- Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf
- NIHR Newcastle Biomedical Research Centre (777377, 634413)
- Universitätsklinikum Hamburg-Eppendorf
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- NIHR Cambridge Biomedical Research Centre
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze
- National Cancer Institute (PS3416, R37CA230636, CA196521, CA150272P3, P30CA008748, P30CA196521)
- National Center for Advancing Translational Sciences
- European Social Fund (PID2019)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, nonalcoholic steatohepatitis, immunotherapy, PD-1, PD-L1 inhibitors, tumor surveillance, CD8+ T cells, T cell exhaustion, TNF-α, TOX, CXCR6, non-alcoholic fatty liver disease, tumour aetiology
- MeSH terms
- Animals, Carcinoma, Hepatocellular, Humans, Immunotherapy, Liver, Liver Neoplasms, Male, Tumor Necrosis Factor-alpha, CD8-Positive T-Lymphocytes, Disease Progression, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Carcinogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NASH limits anti-tumour surveillance in immunotherapy-treated HCC. https://app.cochat.ai/papers/10.1038/s41586-021-03362-0
- The paper
- Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., Müller, F., Sinha, A., Friebel, E., Engleitner, T., Lenggenhager, D., Moncsek, A., Heide, D., Stirm, K., Kosla, J., . . . Heikenwalder, M. (2021). NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. https://doi.org/10.1038/s41586-021-03362-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.